Chronic allograft nephropathy
Chronic Allograft Nephropathy (CAN) is a medical condition affecting the kidneys after a kidney transplant. It is characterized by a gradual loss of kidney function and is considered a leading cause of long-term graft failure. The term "chronic allograft nephropathy" has been largely replaced by the term "interstitial fibrosis and tubular atrophy" (IFTA) without specific etiology, as it more accurately describes the histological findings seen in these patients.
Causes
The exact cause of CAN is multifactorial and includes both immunologic and non-immunologic factors. Immunologic factors involve the recipient's immune response against the transplanted kidney, including acute and chronic rejection episodes. Non-immunologic factors include drug toxicity (especially from calcineurin inhibitors), hypertension, diabetes, and infections.
Symptoms
Symptoms of CAN are often nonspecific and can include a gradual decrease in kidney function, as evidenced by increased serum creatinine levels, decreased glomerular filtration rate (GFR), hypertension, and proteinuria. In many cases, symptoms may not become apparent until significant kidney damage has occurred.
Diagnosis
Diagnosis of CAN involves a combination of clinical assessment, laboratory tests, and histological evaluation of kidney tissue obtained through a biopsy. The biopsy is crucial for distinguishing CAN from acute rejection and other potential causes of kidney dysfunction post-transplantation.
Treatment
Treatment of CAN is challenging and focuses on slowing the progression of the disease. This may involve adjustments in immunosuppressive therapy, management of blood pressure and proteinuria, and addressing any modifiable risk factors such as diabetes and obesity. In cases where graft function continues to decline, dialysis or re-transplantation may be necessary.
Prevention
Preventive strategies for CAN include careful selection of donor and recipient, optimal management of immunosuppression to minimize drug toxicity while preventing rejection, and aggressive management of risk factors such as hypertension and diabetes.
Prognosis
The prognosis for patients with CAN varies. Early detection and intervention can slow the progression of the disease, but many patients eventually experience graft loss and return to dialysis or undergo a second transplant.
This article is a transplant stub. You can help WikiMD by expanding it!
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian